Schizoaffective Disorders Completed Phase 4 Trials for Tocilizumab (DB06273)

Also known as: Schizoaffective disorder / Schizophrenia schizoaffective / Schizoaffective psychosis / Schizo-affective type schizophrenia

IndicationStatusPhase
DBCOND0033299 (Schizoaffective Disorders)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02034474Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of SchizophreniaTreatment